Merck & Co., Inc. (MRK) Discusses HIV Program Updates and Phase III Data from International AIDS Conference Transcript

Merck & Co., Inc. (MRK) Discusses HIV Program Updates and Phase III Data from International AIDS Conference August 3, 2026 8:00 AM EDT Company Participants Peter Dannenbaum - Vice President of Investor Relations Eliav Barr - Chief Medical Officer & Head of Global Clinical Development of Merck Research Laboratories Elizabeth Rhee Brian Foard - Executive VP and President of Specialty, Pharma & Infectious Diseases Gregg Szabo Conference Call Participants Trung Huynh - RBC Capital Markets, Research Division Malcolm Hoffman - BMO Capital Markets Equity Research Alexandria Hammond - Wolfe Research, LLC Geoffrey Meacham - Citigroup Inc., Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Carter Gould - Cantor Fitzgerald & Co., Research Division Jason Gerberry - BofA Securities, Research Division Michael Yee - UBS Investment Bank, Research Division Louise Chen - Scotiabank Global Banking and Markets, Research Division Presentation Operator Welcome to the Merck & Company Inc. Rahway New Jersey USA. Investor Event following the 2026 International AIDS Conference. [Operator Instructions]. I would now like to turn the call over to Mr. Peter Dannenbaum, Senior Vice President, Investor Relations. Sir, you may begin. Peter Dannenbaum Vice President of Investor Relations Thank you, Amanda. Good morning, everyone, and thank you for joining us for Merck's HIV Investor Event following the 26th International AIDS Conference that took place in Rio de Janeiro, Brazil last week. Before we get started, I'd like to remind you that some of the statements that we make today may be considered forward-looking statements within the meaning of the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Such statements are made based on the current beliefs of our company's management and are subject to significant risks and uncertainties.